Daniel L. Morganstein

1.5k total citations
37 papers, 1.1k citations indexed

About

Daniel L. Morganstein is a scholar working on Oncology, Epidemiology and Molecular Biology. According to data from OpenAlex, Daniel L. Morganstein has authored 37 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 13 papers in Epidemiology and 10 papers in Molecular Biology. Recurrent topics in Daniel L. Morganstein's work include Cancer Immunotherapy and Biomarkers (12 papers), Neuroendocrine Tumor Research Advances (11 papers) and Neuroblastoma Research and Treatments (9 papers). Daniel L. Morganstein is often cited by papers focused on Cancer Immunotherapy and Biomarkers (12 papers), Neuroendocrine Tumor Research Advances (11 papers) and Neuroblastoma Research and Treatments (9 papers). Daniel L. Morganstein collaborates with scholars based in United Kingdom, Switzerland and Israel. Daniel L. Morganstein's co-authors include Malcolm G. Parker, Roger White, Mark Christian, James Larkin, Panagiotis Anagnostis, Andromachi Vryonidou, Stavroula Α. Paschou, Dimitrios G. Goulis, Anastasia Dede and Birger Herzog and has published in prestigious journals such as Journal of Clinical Oncology, Molecular and Cellular Biology and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Daniel L. Morganstein

36 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel L. Morganstein United Kingdom 17 425 335 330 279 153 37 1.1k
Jeshmi Jeyabalan United Kingdom 13 215 0.5× 154 0.5× 308 0.9× 49 0.2× 104 0.7× 19 637
Vien Le United States 11 163 0.4× 463 1.4× 595 1.8× 83 0.3× 33 0.2× 20 1.2k
Marcello Filopanti Italy 20 151 0.4× 166 0.5× 509 1.5× 87 0.3× 69 0.5× 41 1.3k
Abhishek Aggarwal United States 21 198 0.5× 166 0.5× 430 1.3× 215 0.8× 16 0.1× 34 1.1k
Toshio Fumoto Japan 10 341 0.8× 62 0.2× 618 1.9× 97 0.3× 62 0.4× 24 1.1k
Dongxing Zhu United Kingdom 22 146 0.3× 219 0.7× 676 2.0× 109 0.4× 21 0.1× 42 1.7k
Masayuki Hosoi Japan 19 140 0.3× 162 0.5× 472 1.4× 162 0.6× 24 0.2× 42 1.4k
Ghi Su Kim South Korea 22 322 0.8× 132 0.4× 723 2.2× 185 0.7× 19 0.1× 45 1.5k
J Minamikawa Japan 12 68 0.2× 203 0.6× 551 1.7× 130 0.5× 91 0.6× 26 1.1k
Marius R. Robciuc Finland 17 566 1.3× 207 0.6× 609 1.8× 400 1.4× 25 0.2× 24 1.8k

Countries citing papers authored by Daniel L. Morganstein

Since Specialization
Citations

This map shows the geographic impact of Daniel L. Morganstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel L. Morganstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel L. Morganstein more than expected).

Fields of papers citing papers by Daniel L. Morganstein

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel L. Morganstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel L. Morganstein. The network helps show where Daniel L. Morganstein may publish in the future.

Co-authorship network of co-authors of Daniel L. Morganstein

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel L. Morganstein. A scholar is included among the top collaborators of Daniel L. Morganstein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel L. Morganstein. Daniel L. Morganstein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wong, Ka-Hing, et al.. (2024). Long-term Clinical Outcomes of Patients With Medullary Thyroid Cancer: A Single Institution, Tertiary Referral Centre Experience. Clinical Oncology. 37. 103686–103686. 1 indexed citations
2.
Farag, Sheima, et al.. (2023). Hyperglycaemia following immune checkpoint inhibitor therapy—Incidence, aetiology and assessment. Diabetic Medicine. 40(4). e15053–e15053. 9 indexed citations
3.
Joharatnam‐Hogan, Nalinie & Daniel L. Morganstein. (2022). Diabetes and cancer: Optimising glycaemic control. Journal of Human Nutrition and Dietetics. 36(2). 504–513. 4 indexed citations
4.
Percik, Ruth, James Larkin, & Daniel L. Morganstein. (2021). Endocrinopathies induced by immune checkpoint inhibitors: the need for clear endocrine diagnosis. The Lancet Oncology. 22(7). 905–907. 4 indexed citations
5.
Hayes, Aimee R., Alexander M. Crawford, Christine Tang, et al.. (2021). Metastatic Medullary Thyroid Cancer: The Role of 68Gallium-DOTA-Somatostatin Analogue PET/CT and Peptide Receptor Radionuclide Therapy. The Journal of Clinical Endocrinology & Metabolism. 106(12). e4903–e4916. 19 indexed citations
6.
Yousaf, Nadia, et al.. (2020). Glucocorticoid use and complications following immune checkpoint inhibitor use in melanoma. Clinical Medicine. 20(2). 163–168. 26 indexed citations
7.
Morganstein, Daniel L., et al.. (2020). Dexamethasone caution. BDJ. 229(7). 398–398. 1 indexed citations
8.
Morganstein, Daniel L.. (2019). Immunotherapy-induced Endocrinopathies: Assessment, Management and Monitoring. Endocrine Abstracts. 1 indexed citations
9.
Paschou, Stavroula Α., Anastasia Dede, Panagiotis Anagnostis, et al.. (2017). Type 2 Diabetes and Osteoporosis: A Guide to Optimal Management. The Journal of Clinical Endocrinology & Metabolism. 102(10). 3621–3634. 144 indexed citations
10.
Wechalekar, Kshama, Rajdeep Khattar, Stuart D. Rosen, et al.. (2017). Histologically Proven Myocardial Carcinoid Metastases: The Value of Multimodality Imaging. Canadian Journal of Cardiology. 33(10). 1336.e9–1336.e12. 2 indexed citations
11.
12.
Balachandran, K., Alicia Okines, R. Gunapala, Daniel L. Morganstein, & Sanjay Popat. (2015). Resolution of severe hyponatraemia is associated with improved survival in patients with cancer. BMC Cancer. 15(1). 163–163. 29 indexed citations
13.
Morganstein, Daniel L., et al.. (2010). Human fetal mesenchymal stem cells differentiate into brown and white adipocytes: a role for ERRα in human UCP1 expression. Cell Research. 20(4). 434–444. 61 indexed citations
14.
Morganstein, Daniel L., et al.. (2009). Human fetal mesenchymal stem cells can differentiate into white and brown adipocytes, and reveal a role for ERR[alpaha] in human UCP1 expression. 19(5). 774–5. 3 indexed citations
15.
Morganstein, Daniel L., David H. Lewis, James E. Jackson, et al.. (2009). The role of arterial stimulation and simultaneous venous sampling in addition to cross-sectional imaging for localisation of biochemically proven insulinoma. European Radiology. 19(10). 2467–2473. 29 indexed citations
16.
Morganstein, Daniel L., Mark Christian, J Turner, Malcolm G. Parker, & R White. (2007). Conditionally immortalized white preadipocytes: a novel adipocyte model. Journal of Lipid Research. 49(3). 679–685. 18 indexed citations
17.
Morganstein, Daniel L. & Malcolm G. Parker. (2007). Role of nuclear receptor coregulators in metabolism. Expert Review of Endocrinology & Metabolism. 2(6). 797–807. 2 indexed citations
18.
White, Roger, et al.. (2007). Role of RIP140 in metabolic tissues: Connections to disease. FEBS Letters. 582(1). 39–45. 59 indexed citations
19.
Christian, Mark, Daniel L. Morganstein, Asha Seth, et al.. (2007). Receptor Interacting Protein 140 Regulates Expression of Uncoupling Protein 1 in Adipocytes through Specific Peroxisome Proliferator Activated Receptor Isoforms and Estrogen-Related Receptor α. Molecular Endocrinology. 21(7). 1581–1592. 85 indexed citations
20.
Morganstein, Daniel L., N Mendoza, Nicola H. Strickland, & Karim Meeran. (2005). Low TSH in a Patient with Primary Hypothyroidism. Journal of the Royal Society of Medicine. 98(9). 417–418. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jeshmi Jeyabalan Breakdown of academic impact, for papers by Vien Le Breakdown of academic impact, for papers by Marcello Filopanti Breakdown of academic impact, for papers by Abhishek Aggarwal Breakdown of academic impact, for papers by Toshio Fumoto Breakdown of academic impact, for papers by Dongxing Zhu Breakdown of academic impact, for papers by Masayuki Hosoi Breakdown of academic impact, for papers by Ghi Su Kim Breakdown of academic impact, for papers by J Minamikawa Breakdown of academic impact, for papers by Marius R. Robciuc
Rankless by CCL
2026